Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
ACE-27 and ASA score effectively categorize patients' risks in adjuvant radiotherapy for head and neck cancer, proving more predictive of overall survival than ECOG-PS. These results underscore the importance of objective comorbidity assessment and suggest further prospective studies.
Authors
- Lars Schüttrumpf (ORCID: https://orcid.org/0000-0003-3305-3806)
- Sebastian Marschner (ORCID: https://orcid.org/0000-0002-8121-358X)
- Cornelius Maihöfer (ORCID: https://orcid.org/0000-0002-0506-4519)
- D. Reitz (ORCID: https://orcid.org/0000-0003-0539-9092)
- Erik Haehl (ORCID: https://orcid.org/0000-0002-2222-7324)
- Claus Belka (ORCID: https://orcid.org/0000-0002-1287-7825)
- Kristian Unger (ORCID: https://orcid.org/0000-0002-0374-2320)
- Horst Zitzelsberger (ORCID: https://orcid.org/0000-0002-5411-9213)
- Philipp Baumeister (ORCID: https://orcid.org/0000-0003-2759-4737)
- Richard Späth
- N. Kienlechner
- Julia Heß (ORCID: https://orcid.org/0000-0001-9860-1426)
- Ulrike Pflugradt
- Franziska Walter (ORCID: https://orcid.org/0000-0001-7912-322X)
Institutions
- German Cancer Research Center (DE)
- Helmholtz Zentrum München (DE)
- LMU Klinikum (DE)
- German Centre for Cardiovascular Research (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1007/s00066-024-02282-y
- Citations
- 3
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.74